Biotech Top Losers: Xencor (NASDAQ:XNCR), Flex Pharma (NASDAQ:FLKS), Minerva Neurosciences (NASDAQ:NERV), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Xencor, Inc. (NASDAQ:XNCR), reported top-line interim results from a Phase 1a study for XmAb®7195. The data show rapid reduction of circulating free IgE levels to below the limit of detection in 90% of XmAb7195 treated subjects that had detectable free IgE pre-dose, including those at the lowest dose evaluated of 0.3 mg/kg. Total IgE levels were also reduced in a parallel fashion. On Thursday shares of Xencor, Inc. (NASDAQ:XNCR) closed at $15.53.

IPO for Flex Pharm (NASDAQ: FLKS) opened for trading at $19 after pricing 5,400,000 shares of common stock at a public offering price of $16 per share. Flex Pharma, Inc. (NASDAQ:FLKS) in last trading activity moved down -6.56% to close at $14.95.

Minerva Neurosciences, Inc. (NASDAQ:NERV) on 21st January announced that preliminary results from a Phase 1 clinical study showed that treatment with MIN-202, a selective orexin-2 antagonist, resulted in significant improvements in sleep onset and sleep duration in patients with comorbid insomnia related to major depressive disorder (MDD). Preliminary results from two additional Phase 1 studies also suggest that MIN-202 is well tolerated and possesses advantageous pharmacokinetic and pharmacodynamic features. On last trading day Minerva Neurosciences, Inc. (NASDAQ:NERV) moved down -6.52% to close at $4.59. Its volatility for the week is 6.77% while volatility for the month is 11.67%. Minerva Neurosciences, Inc. (NASDAQ:NERV) monthly performance is -17.00%.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported a fourth-quarter net loss to company of $176.66 million or $0.74 per share, compared to profit of $44.29 million or $0.19 per share, prior year. Adjusted loss per share was $0.55, for the quarter. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has 0.50% insider ownership while its institutional ownership stands at 98.40%. In last trading activity company’s stock closed at $114.14.

Canaccord Genuity reaffirmed their buy rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE) in a research note issued to investors on Tuesday. The firm currently has a $30.00 price target on the stock. On last trading day Xenon Pharmaceuticals Inc. (NASDAQ:XENE) moved down -5.53% to close at $17.24. Its volatility for the week is 7.43% while volatility for the month is 9.19%. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) monthly performance is -13.41%.

Biotech Stocks New Lows: Histogenics Corporation (NASDAQ:HSGX), Cleveland BioLabs (NASDAQ:CBLI), Theravance Inc. (NASDAQ:THRX), Celsion Corp. (NASDAQ:CLSN), VIVUS Inc. (NASDAQ:VVUS)

BTIG Research initiated coverage on shares of Histogenics Corp (NASDAQ:HSGX) in a research report released on Friday morning, TheFlyOnTheWall.com reports. The firm issued a buy rating and a $13.00 price objective on the stock. On Wednesday shares of Histogenics Corporation (NASDAQ:HSGX) closed at $7.11.

Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced that at a special meeting of stockholders held on January 27, 2015, stockholders authorized the Company’s Board of Directors to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1:2 to 1:20. Cleveland BioLabs, Inc. (NASDAQ:CBLI) in last trading activity moved down -22.71% to close at $3.71. Company weekly performance is -33.75% while its quarterly performance stands at -55.83%. Cleveland BioLabs, Inc. (NASDAQ:CBLI) is -78.68% away from its 52 week high.

On last trading day Theravance Inc. (NASDAQ:THRX) moved down -4.70% to close at $10.94. Its volatility for the week is 6.06% while volatility for the month is 5.83%. THRX’s sales growth for past 5 years was -27.00% and its EPS growth for past 5 years was -1.80%. Theravance Inc. (NASDAQ:THRX) monthly performance is -27.21%.

Celsion Corporation (NASDAQ:CLSN) on 13 January has announced the submission of its Phase I clinical trial protocol to the U.S. Food and Drug Administration (FDA) for GEN-1, a DNA-based immunotherapy for cancer treatment. Celsion Corp. (NASDAQ:CLSN) has 0.30% insider ownership while its institutional ownership stands at 28.60%. In last trading activity company’s stock closed at $2.20.

On January 22, 2015, Samuel F. Colin, M.D. notified VIVUS, Inc., VIVUS Inc. (NASDAQ:VVUS) or the Company, of his decision to resign from the Company’s Board of Directors, effective immediately. On last trading day VIVUS Inc. (NASDAQ:VVUS) moved down -2.94% to close at $2.64. Its volatility for the week is 5.88% while volatility for the month is 6.41%. VVUS’s sales growth for past 5 years was -0.60% and its EPS growth for past 5 years was -65.30%. VIVUS Inc. (NASDAQ:VVUS) monthly performance is -10.81%.

Biotech Stocks New Highs: Aldeyra Therapeutics (NASDAQ:ALDX), Radius Health (NASDAQ:RDUS), Illumina Inc. (NASDAQ:ILMN), Ocular Therapeutix (NASDAQ:OCUL), Codexis (NASDAQ:CDXS)

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer and Mr. Stephen Tulipano, Chief Financial Officer of Aldeyra, will participate in the Canaccord Genuity Rare Disease, BioPharma One-on-One Day, being held on Tuesday, February 3, 2015 in New York, NY. on Facebook On Wednesday shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) closed at $11.59.

Radius Health, Inc. (NASDAQ:RDUS) announced the closing of its previously announced public offering of 4,600,000 shares of common stock at a public offering price of $36.75 per share, including 600,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares of common stock. Radius Health, Inc. (NASDAQ:RDUS) in last trading activity increased 5.10% to close at $46.55. Company weekly performance is 26.15% while its quarterly performance stands at 135.10%. Radius Health, Inc. (NASDAQ:RDUS) is 1.24% away from its 52 week high.

Illumina Inc. (NASDAQ:ILMN) announced Gross margin for fiscal 2014 was 69.7% compared to 64.2% in the prior year; the prior year period included impairment charges of $25.2 million related to the discontinuation of a non-core product line. Excluding the effect of non-cash stock compensation expense, legal contingencies, amortization of acquired intangible assets, and impairments, non-GAAP gross margin was 71.7% for fiscal 2014 compared to 70.1% in the prior year. On last trading day Illumina Inc. (NASDAQ:ILMN) fell -2.65% to close at $197.86. Its volatility for the week is 4.64% while volatility for the month is 4.19%. ILMN’s sales growth for past 5 years was 19.90% and its EPS growth for past 5 years was 24.60%. Illumina Inc. (NASDAQ:ILMN) monthly performance is 5.13%.

Ocular Therapeutix™, Inc. (NASDAQ:OCUL), announced on 21 January enrollment of the first patient in a Phase 2 clinical trial to evaluate the safety and efficacy of Sustained Release Dexamethasone (OTX-DP), an ophthalmic corticosteroid for the treatment of inflammatory dry eye disease. Ocular Therapeutix’s dexamethasone is being developed for administration as a one-time, bioresorbable intracanalicular plug for drug release to the ocular surface for up 30 days. Ocular Therapeutix, Inc. (NASDAQ:OCUL) has 3.30% insider ownership while its institutional ownership stands at 70.10%. In last trading activity company’s stock closed at $28.83.

Zacks cut shares of Codexis (NASDAQ:CDXS) to a neutral rating in a research report sent to investors on Friday morning. The firm currently has $3.10 price target on the stock.On last trading day Codexis, Inc. (NASDAQ:CDXS) increased 3.10% to close at $3.33. Its volatility for the week is 6.74% while volatility for the month is 7.08%. CDXS’s sales growth for past 5 years was -8.80% and its EPS growth for past 5 years was 43.60%. Codexis, Inc. (NASDAQ:CDXS) monthly performance is 30.59%.

Biotech Stocks Touched New Highs: Array BioPharma (NASDAQ:ARRY), Novavax (NASDAQ:NVAX), Illumina Inc. (NASDAQ:ILMN), Pharmacyclics Inc. (NASDAQ:PCYC), Dyax Corp. (NASDAQ:DYAX)

Array BioPharma Inc. (NASDAQ:ARRY) will Report Financial Results For The Second Quarter Of Fiscal 2015 On February 3, 2015. On Tuesday shares of Array BioPharma, Inc. (NASDAQ:ARRY) closed at $7.64. Company’s sales growth for last 5 years was 11.00% and EPS growth for next 5 years is recorded as 10.00%.

Novavax, Inc. (NASDAQ:NVAX), announced that Stanley C. Erck, President and CEO, presented at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015. Novavax, Inc. (NASDAQ:NVAX) in last trading activity moved up 2.89% to close at $7.82. Company weekly performance is 7.27% while its quarterly performance stands at 52.44%. Novavax, Inc. (NASDAQ:NVAX) is 1.03% away from its 52 week high.

Illumina Inc. (NASDAQ:ILMN) announced Gross margin in the fourth quarter of 2014 was 75.1% compared to 66.9% in the prior year period. Excluding the effect of non-cash stock compensation expense, legal contingencies, amortization of acquired intangible assets, and impairments, non-GAAP gross margin was 72.3% for the fourth quarter of 2014 compared to 71.4% in the prior year period. On last trading day Illumina Inc. (NASDAQ:ILMN) moved up 0.78% to close at $203.25. Its volatility for the week is 3.61% while volatility for the month is 3.92%. ILMN’s sales growth for past 5 years was 19.90% and its EPS growth for past 5 years was 24.60%. Illumina Inc. (NASDAQ:ILMN) monthly performance is 9.15%.

On January 16, 2015, the Compensation Committee of Pharmacyclics, Inc. (NASDAQ:PCYC) approved the grant of Restricted Stock Units pursuant to the 2014 Equity Incentive Award Plan (the “RSUs”) to certain of the Company’s officers including in the amounts: 15,000 to Mahkam Zanganeh, the Company’s Chief Operating Officer and 22,000 to Manmeet Soni, the Company’s Chief Financial Officer and Treasurer. All such RSUs vest 25% on each of February 28, 2016, February 28, 2017, February 28, 2018 and February 28, 2019.Pharmacyclics Inc. (NASDAQ:PCYC) has 0.50% insider ownership while its institutional ownership stands at 76.10%. In last trading activity company’s stock closed at $166.65.

Zacks cut shares of Dyax Corp. (NASDAQ:DYAX) from an outperform rating to a neutral rating in a research note issued to investors on Tuesday. The firm currently has $16.40 price target on the stock. On last trading day Dyax Corp. (NASDAQ:DYAX) moved up 1.06% to close at $16.16. Its volatility for the week is 5.31% while volatility for the month is 4.62%. DYAX’s sales growth for past 5 years was 4.40% and its EPS growth for past 5 years was 24.80%. Dyax Corp. (NASDAQ:DYAX) monthly performance is 14.37%.

Biotech Losers: Actinium Pharmaceuticals (NYSEMKT:ATNM), EPIRUS Biopharmaceuticals (NASDAQ:EPRS), GenVec (NASDAQ:GNVC), Genetic Technologies Limited (NASDAQ:GENE), Corium International (NASDAQ:CORI)

Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) announced that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration (FDA) for the company’s Iomab-B drug candidate currently undergoing final preparations to start the pivotal Phase 3 trial in mid-2015. On Tuesday shares of Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) closed at $5.54.

EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), announced that it has commenced an underwritten public offering of shares of its common stock. EPIRUS intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering. EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) in last trading activity moved down -11.32% to close at $5.72. Company weekly performance is -23.43% while its quarterly performance stands at 14.40%. EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) is -67.13% away from its 52 week high.

Roth Capital set a $8.00 target price on shares of GenVec (NASDAQ:GNVC) stock in a research note issued on Friday. The firm currently has a a “buy” rating on the stock. Roth Capital’s price objective would suggest a potential upside of 132.56% from the stock’s previous close. On last trading day GenVec, Inc. (NASDAQ:GNVC) moved down -6.01% to close at $3.44. Its volatility for the week is 9.77% while volatility for the month is 12.10%. GNVC’s sales growth for past 5 years was -24.50% and its EPS growth for past 5 years was 24.60%. GenVec, Inc. (NASDAQ:GNVC) monthly performance is 68.63%.

On 21st January Genetic Technologies Limited (NASDAQ: GENE) announced that it has entered into a A$24 million Standby Equity Placement Facility Agreement (the “Facility” or “Agreement”) with the Kentgrove Capital Growth Fund (“Kentgrove Capital”), an investment fund managed by Kentgrove Capital Pty Ltd, a Melbourne-based investment and advisory firm, to strengthen the Company’s funding position. Genetic Technologies Limited (NASDAQ:GENE) has 1.50% insider ownership while its institutional ownership stands at 2.70%. In last trading activity company’s stock closed at $1.27.

On last trading day Corium International, Inc. (NASDAQ:CORI) moved down -5.56% to close at $6.63. Its volatility for the week is 6.31% while volatility for the month is 6.52%. Corium International, Inc. (NASDAQ:CORI) monthly performance is 2.95%.

Biotech Gainers: ZIOPHARM Oncology (NASDAQ:ZIOP), Advaxis (NASDAQ:ADXS), Intrexon Corporation (NYSE:XON), Radius Health (NASDAQ:RDUS), Puma Biotechnology (NYSE:PBYI)

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) and Intrexon Corp. announced on 14 January that they have entered into a license agreement with The University of Texas M.D. Anderson Cancer Center to develop cancer treatments. On Tuesday shares of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) closed at $8.93.

Advaxis, Inc. (NASDAQ:ADXS), on 22 January announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1 clinical study of ADXS-HER2 (ADXS31-164) for the treatment of patients with metastatic HER2 expressing solid tumors. Advaxis, Inc. (NASDAQ:ADXS) in last trading activity increased 20.17% to close at $9.89. Company weekly performance is -15.90% while its quarterly performance stands at 197.00%. Advaxis, Inc. (NASDAQ:ADXS) is -28.02% away from its 52 week high.

Intrexon Corporation (NYSE: XON), announced the closing of its previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 562,500 shares of common stock at the public offering price of $27.00 per share. The exercise of the underwriters’ option brought the total number of shares of common stock sold by Intrexon to 4,312,500 shares and increased the total gross proceeds raised in the offering to approximately $116.4 million, before deducting the underwriting discounts, commissions and estimated expenses. On last trading day Intrexon Corporation (NYSE:XON) increased 8.58% to close at $31.88. Its volatility for the week is 11.41% while volatility for the month is 10.14%. Intrexon Corporation (NYSE:XON) monthly performance is 21.73%.

Radius Health, Inc. (NASDAQ:RDUS) on 22 January announced that it has priced its public offering of 4,000,000 shares of its common stock at a public offering price of $36.75 per share. In addition, the Company has granted the underwriters an option to purchase up to an additional 600,000 shares of its common stock, exercisable for 30 days. Radius Health, Inc. (NASDAQ:RDUS) has 3.60% insider ownership while its institutional ownership stands at 47.10%. In last trading activity company’s stock closed at $44.29.

RBC Capital began coverage on shares of Puma Biotechnology (NYSE:PBYI) in a report released on Thursday, TheFlyOnTheWall.com reports. The firm issued an outperform rating and a $282.00 price objective on the stock. On last trading day Puma Biotechnology, Inc. (NYSE:PBYI) increased 6.16% to close at $226.13. Its volatility for the week is 8.84% while volatility for the month is 5.69%. Puma Biotechnology, Inc. (NYSE:PBYI) monthly performance is 19.04%.

Biotech Bullish Stocks: Array BioPharma (NASDAQ:ARRY), ZIOPHARM Oncology (NASDAQ:ZIOP), Athersys (NASDAQ:ATHX), Curis (NASDAQ:CRIS), Kite Pharma (NASDAQ:KITE)

Array BioPharma Inc. (NASDAQ:ARRY) announced on 23 January that it has reached a definitive agreement to acquire the worldwide rights to encorafenib from Novartis Pharma.On Monday shares of Array BioPharma, Inc. (NASDAQ:ARRY) closed at $7.80. Company’s sales growth for last 5 years was 11.00% and EPS growth for next 5 years is recorded as 10.00%.

ZIOPHARM Oncology (NASDAQ:ZIOP) was upgraded by investment analysts at BMO Capital Markets from an “underperform” rating to an “outperform” rating in a note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm currently has a $15.00 price target on the stock, up from their previous price target of $1.00. BMO Capital Markets’ target price would suggest a potential upside of 69.11% from the company’s current price. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) in last trading activity moved up 10.50% to close at $8.00. Company weekly performance is -1.36% while its quarterly performance stands at 185.71%. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) is -15.79% away from its 52 week high.

Athersys, Inc. (NASDAQ:ATHX) and the Cell Therapy Catapult on 22 January are pleased to announce that Athersys Limited has been awarded a grant from Innovate UK, formerly the Technology Strategy Board, which will support a Phase 2a clinical study evaluating the administration of MultiStem® cell therapy to acute respiratory distress syndrome (ARDS) patients. On last trading day Athersys, Inc. (NASDAQ:ATHX) moved up 7.35% to close at $2.19. Its volatility for the week is 9.51% while volatility for the month is 9.13%. ATHX’s sales growth for past 5 years was -5.00% and its EPS growth for past 5 years was 11.00%. Athersys, Inc. (NASDAQ:ATHX) monthly performance is 64.66%.

Curis, Inc. (NASDAQ:CRIS) on 22 January announced that it has entered into an exclusive collaboration agreement with Aurigene Discovery Technologies Limited, an independent, wholly owned subsidiary of Dr. Reddy’s Laboratories Ltd. (RDY). Curis, Inc. (NASDAQ:CRIS) has 0.10% insider ownership while its institutional ownership stands at 42.10%. In last trading activity company’s stock closed at $1.94.

Kite Pharma, Inc., (NASDAQ:KITE) on 22 January announced that the Company has expanded its agreement with Tel Aviv Sourasky Medical Center to research and develop novel approaches to CAR T cell therapy, the technology underlying Kite’s most advanced programs in cancer immunotherapy. Under the agreement, Kite will collaborate with Professor Zelig Eshhar, Ph.D., the leading pioneer in CAR T cell research and Chair of Immunology Research within the Tel Aviv Sourasky Medical Center’s Division of Research and Development. On last trading day Kite Pharma, Inc. (NASDAQ:KITE) moved up 5.94% to close at $71.37. Its volatility for the week is 12.01% while volatility for the month is 10.09%. Kite Pharma, Inc. (NASDAQ:KITE) monthly performance is 38.56%.

Biotech Active Stocks: Array BioPharma (NASDAQ:ARRY), NPS Pharmaceuticals (NASDAQ:NPSP), Gilead Sciences Inc. (NASDAQ:GILD), Achillion Pharmaceuticals (NASDAQ:ACHN)

Array BioPharma Inc. (NASDAQ:ARRY) will report financial results for the second quarter of fiscal 2015 and hold a conference call to discuss those results on Tuesday February 3 2015. On Monday shares of Array BioPharma, Inc. (NASDAQ:ARRY) closed at $7.80. Company’s sales growth for last 5 years was 11.00% and EPS growth for next 5 years is recorded as 10.00%.

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company focused on the development of therapeutic products, announced on 23 January that its drug Natpara for rare hormonal disorder has won the US Food and Drug Administration’s (FDA) approval, endorsing a bet by Shire PLC (ADR) (NASDAQ:SHPG) on the drug’s approval and thus validating the company’s $5.2 billion acquisition of NPS. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) in last trading activity advanced 0.64% to close at $45.93. Company weekly performance is 1.06% while its quarterly performance stands at 57.94%. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) is 0.09% away from its 52 week high.

American drugmaker Gilead Sciences Inc (NASDAQ:GILD) has expanded its Hepatitis C generic licensing agreements with Indian partners to include an investigational drug GS-5816. On last trading day Gilead Sciences Inc. (NASDAQ:GILD) advanced 1.49% to close at $107.11. Its volatility for the week is 2.98% while volatility for the month is 3.24%. GILD’s sales growth for past 5 years was 16.00% and its EPS growth for past 5 years was 11.90%. Gilead Sciences Inc. (NASDAQ:GILD) monthly performance is 19.74%.

Achillion Pharmaceuticals (NASDAQ:ACHN) CEO Milind Deshpande sold 100,000 shares of Achillion Pharmaceuticals stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $15.00, for a total value of $1,500,000.00. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has 44.11% insider ownership while its institutional ownership stands at 95.30%. In last trading activity company’s stock closed at $15.60.

Top Biotech Gainers: Array BioPharma (NASDAQ:ARRY), ZIOPHARM Oncology (NASDAQ:ZIOP), Curis (NASDAQ:CRIS), Alnylam Pharmaceuticals (NASDAQ:ALNY), Minerva Neurosciences (NASDAQ:NERV)

Array Biopharma (NASDAQ:ARRY) was the target of a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 18,577,143 shares, a decrease of 12.3% from the December 15th total of 21,193,329 shares, Stock Ratings News reports. On Thursday shares of Array BioPharma, Inc. (NASDAQ:ARRY) closed at $5.05. Company’s sales growth for last 5 years was 11.00% and EPS growth for next 5 years is recorded as 10.00%.

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) and Intrexon Corp. announced on 14 January that they have entered into a license agreement with The University of Texas M.D. Anderson Cancer Center to develop cancer treatments.ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) in last trading activity advanced 7.00% to close at $7.34. Company weekly performance is -17.25% while its quarterly performance stands at 187.84%. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) is -22.74% away from its 52 week high.

Curis Inc., (NASDAQ:CRIS) a biotech based in Lexington, announced a deal Wednesday with an Indian drug discovery firm to develop cancer drugs that can be administered in pill form. On last trading day Curis, Inc. (NASDAQ:CRIS) advanced 17.48% to close at $1.68. Its volatility for the week is 9.28% while volatility for the month is 8.84%. CRIS’s sales growth for past 5 years was 12.30% and its EPS growth for past 5 years was 4.60%. Curis, Inc. (NASDAQ:CRIS) monthly performance is 43.59%.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading RNAi therapeutics company, announced the pricing of an underwritten registered public offering of 4,736,842 shares of its common stock at a public offering price of $95 per share. All of the shares in the offering are to be sold by Alnylam. The offering is expected to close on or about January 26, 2015, subject to the satisfaction of customary closing conditions. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has 8.10% insider ownership while its institutional ownership stands at 78.80%. In last trading activity company’s stock closed at $93.17.

Minerva Neurosciences Inc. (NASDAQ:NERV)’s preliminary results from a Phase 1 clinical study showed that treatment with MIN-202, a selective orexin-2 antagonist, resulted in significant improvements in sleep onset and sleep duration in patients with comorbid insomnia related to major depressive disorder (MDD). On last trading day Minerva Neurosciences, Inc. (NASDAQ:NERV) advanced 16.59% to close at $5.09. Its volatility for the week is 7.66% while volatility for the month is 11.12%. Minerva Neurosciences, Inc. (NASDAQ:NERV) monthly performance is -10.23%.

Top Biotech Losers: Advaxis (NASDAQ:ADXS), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Otonomy (NASDAQ:OTIC), Enanta Pharmaceuticals (NASDAQ:ENTA), FibroGen (NASDAQ:FGEN)

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1 clinical study of ADXS-HER2 (ADXS31-164) for the treatment of patients with metastatic HER2 expressing solid tumors. On Thursday shares of Advaxis, Inc. (NASDAQ:ADXS) closed at $7.43.

OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced that a phase III study (AFFINITY) on custirsen has passed the interim futility analysis and is continuing as per the recommendation of the Independent Data Monitoring Committee. OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) in last trading activity decreased -7.62% to close at $2.06. Company weekly performance is -9.65% while its quarterly performance stands at -6.36%. OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) is -85.54% away from its 52 week high.

Otonomy, Inc. (NASDAQ:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, announced the pricing of its follow-on public offering of 2,550,000 shares of its common stock at a price to the public of $29.25 per share, for total gross proceeds of approximately $75 million before deducting underwriting discounts and commissions and other offering expenses. On last trading day Otonomy, Inc. (NASDAQ:OTIC) decreased -14.31% to close at $29.34. Its volatility for the week is 8.73% while volatility for the month is 7.36%. Otonomy, Inc. (NASDAQ:OTIC) monthly performance is -19.59%.

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, on 16 January announced that the European Commission has granted marketing authorizations for AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets)1,2 with or without ribavirin (RBV) for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.1,2 The European Commission has also approved VIEKIRAX for use with RBV for the treatment of patients with genotype 4 (GT4) chronic HCV infection. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has 4.70% insider ownership while its institutional ownership stands at 82.10%. In last trading activity company’s stock closed at $46.00.

FibroGen (NASDAQ:FGEN) was downgraded by research analysts at Goldman Sachs from a “buy” rating to a “neutral” rating in a report released on Friday, TheFlyOnTheWall.com reports. They currently have a $32.00 target price on the stock. Goldman Sachs’ price objective suggests a potential downside of 5.60% from the stock’s previous close. On last trading day FibroGen, Inc. (NASDAQ:FGEN) decreased -6.32% to close at $29.81. Its volatility for the week is 7.81% while volatility for the month is 8.50%. FibroGen, Inc. (NASDAQ:FGEN) monthly performance is 8.56%.